发明名称 HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS.
摘要 The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins and antigen binding protein-FGF21 fusions, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.
申请公布号 MX2012011986(A) 申请公布日期 2013.03.05
申请号 MX20120011986 申请日期 2011.04.13
申请人 AMGEN INC.* 发明人 SHAW-FEN SYLVIA HU;IAN FOLTZ;YANG LI;CHADWICK TERENCE KING;JEONGHOON SUN;MARK LEO MICHAELS;ROGER FACHINI;JI LU;SEOG JOON HAN;SUSIE MIKI HARRIS
分类号 C07K16/28;A61K39/395;A61P3/10 主分类号 C07K16/28
代理机构 代理人
主权项
地址